Korro Bio Inc. (KRRO)
21.30
-1.66 (-7.23%)
At close: Mar 04, 2025, 12:51 PM
Company Description
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases.
Korro Bio, Inc. is based in Cambridge, Massachusetts.
Korro Bio Inc.

Country | United States |
IPO Date | Oct 3, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 95 |
CEO | Dr. Ram Aiyar MBA, Ph.D. |
Contact Details
Address: One Kendall Square Cambridge, Massachusetts United States | |
Website | https://www.korrobio.com |
Stock Details
Ticker Symbol | KRRO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001703647 |
CUSIP Number | 500946108 |
ISIN Number | US5009461089 |
Employer ID | 47-2324450 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Ram Aiyar MBA, Ph.D. | Chief Executive Officer, President, Interim Principal Financial Officer & Director |
Todd Chappell M.B.A. | Chief Operating Officer |
Vineet Agarwal M.B.A. | Chief Financial Officer (Leave of Absence) |
Andrew Fraley Ph.D. | Co-Founder & Advisor |
Dr. Jean-Francois Formela M.D., MBA | Co-Founder & Independent Director |
Dr. Joshua Rosenthal Ph.D. | Co-Founder & Advisor |
Jeffrey M. Cerio J.D., Pharm.D. | Senior Vice President & General Counsel |
Nessan Bermingham Ph.D. | Co-Founder & Independent Chairman of the Board |
Oliver Dolan | Interim Principal Accounting Officer |
Stephanie Engels | Senior Vice President and Head of People & Culture |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | SCHEDULE 13G | Filing |
Feb 11, 2025 | 3 | Filing |
Feb 11, 2025 | 8-K | Current Report |
Feb 05, 2025 | 4 | Filing |
Feb 05, 2025 | SCHEDULE 13G | Filing |
Feb 05, 2025 | 4 | Filing |
Feb 05, 2025 | 4 | Filing |
Feb 05, 2025 | 4 | Filing |
Feb 05, 2025 | 4 | Filing |